Os therapies provides regulatory update on rare pediatric cancer immunotherapy candidate ost-her2 for human osteosarcoma

New york--(business wire)--os therapies (nyse-a: ostx) (“os therapies” or “the company”), a clinical-stage immunotherapy and antibody drug conjugate (adc) biopharmaceutical company, today provided a regulatory update for its ost-her2 listeria monocytogenes (lm) immunotherapeutic cancer biologic drug candidate in the prevention or delay of fully-resected, recurrent, lung metastatic osteosarcoma. “we are making rapid progress in putting together an appropriate data package to achieve accelerated.
OST Ratings Summary
OST Quant Ranking